切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (01) : 54 -58. doi: 10.3877/cma.j.issn.1674-6902.2020.01.011

论著

探讨TGFβ1、PDGF、VEGF对特发性肺纤维化诊断及病情评估的临床意义
孙莹1, 宋晓萍1, 孙伟1,†()   
  1. 1. 116001　辽宁，大连大学附属中山医院呼吸一科
  • 收稿日期:2019-10-11 出版日期:2020-02-25
  • 通信作者: 孙伟
  • 基金资助:
    大连市卫健委专项基金(1811114)

Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis

ying Sun1, yang Peifu1, wei Sun1,†()   

  1. 1. Department of Respiratory Medicine, Affiliated Zhongshan Hospital, Dalian University, Dalian 116001, China
  • Received:2019-10-11 Published:2020-02-25
  • Corresponding author: wei Sun
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙莹, 宋晓萍, 孙伟. 探讨TGFβ1、PDGF、VEGF对特发性肺纤维化诊断及病情评估的临床意义[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 54-58.

ying Sun, yang Peifu, wei Sun. Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 54-58.

目的

探讨分泌转化生长因子-β、血小板衍生生长因子、血管内皮生长因子在特发性肺纤维化(IPF)患者支气管肺泡灌洗液(BALF)和血清中的表达水平及评估病情进展的临床意义。

方法

选择2014年1月至2018年12月在我院呼吸科诊治的35例IPF患者作为观察组，18例肺结节病患者(Ⅰ期)作为对照组；采用免疫印迹观察TGFβ1、PDGF、VEGF在IPF患者血清中是否存在表达；用酶联免疫吸附法(ELISA)观察2组患者BALF和血清中TGFβ1、PDGF、VEGF的表达水平；最后分析IPF患者BALF和血清中TGFβ1、PDGF、VEGF表达水平与肺功能及血氧饱和度的相关性。

结果

TGFβ1、PDGF、VEGF细胞印在IPF患者血清存在表达；与对照组相比，BALF及血清中的TGFβ1、PDGF、VEGF表达上调(P<0.05)；IPF组患者BALF及血清中TGFβ1、PDGF、VEGF表达水平与肺功能中FVC%、FEV1%和DLCO%呈负性相关(P<0.05)；与血氧饱和度也呈显著负相关(P<0.05)。

结论

IPF患者BALF和血清中TGFβ1、PDGF、VEGF的表达水平明显升高；TGFβ1、PDGF、VEGF与患者的肺功能及血氧饱和度呈负相关，可作为评估IPF患者病情的临床评价指标。

关键词: 特发性肺纤维化, 分泌转化生长因子-β, 血小板衍生生长因子, 血管内皮生长因子
Objective

To investigate the expression and clinical significance of transforming growth factor beta 1 (TGFβ1), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in the patients with idiopathic pulmonary fibrosis (IPF).

Methods

A total of 35 IPF patients were selected who were admitted in our hospital from January 2014 to December 2018 as the IPF group and 18 patients with pulmonary sarcoidosis of Stage Ⅰ who were admitted in our hospital at the same period were taken as the control group. Firstly, Western blotting method was employed to observe whether the TGFβ1, PDGF and VEGF expressed in the serum. Secondly, the expression levels of TGFβ1, PDGF and VEGF in the bronchoalveolar lavage fluid (BALF) and in the serum were detected by enzyme-linked immunosorbent assay. Finally, the correlations of TGFβ1, PDGF and VEGF with the pulmonary functions and the blood oxygen saturation were analyzed.

Results

Expression of TGFβ1, PDGF and VEGF exists in the serum of the IPF patients. The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were significantly higher in the IPF group than the control group (P<0.05). The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were negatively correlated with FVC%, FEV1% and DLCO%pred in the IPF group, while they were negatively correlated with the degree of blood oxygen saturation.

Conclusion

The expression levels of TGFβ1, PDGF and VEGF in the serum and in the BALF increase in the IPF patients. They are negatively correlated with the pulmonary functions and the degree of blood oxygen saturation, which can be used as a clinical effective marker for disease monitoring and severity evaluation.

Key words: Idiopathic pulmonary fibrosis, Transforming growth factor-β, Platelet derived growth factor, Vascular endothelial growth factor
图1 结节病与IPF的CT影像学表现
图2 免疫印迹检测各组TGFβ1、PDGF、VEGF的表达水平
表1 两组患者BALF液中TGFβ1、PDGF、VEGF的表达变化
组　别 例数 BALF液
TGF-β1(μ/ml) PDGF(μ/ml) VEGF(μ/ml)
IPF组 35 523.27±285.68 465.01±187.71 329.08±107.71
对照组 18 206.03±109.87 185.01±123.71 129.01±106.09
t值   5.013 4.203 3.403
P值   0.000 0.000 0.000
表2 两组患者血清中TGFβ1、PDGF、VEGF的表达变化
组　别 例数 血清
TGF-β1(μ/ml) PDGF(μ/ml) VEGF(μ/ml)
IPF组 35 823.27±405.76 700.78±377.54 590.12±221.23
对照组 18 346.03±219.87 290.01±213.06 227.01±195.29
t值   7.513 6.783 5.723
P值   0.000 0.000 0.000
表3 IPF患者TGFβ1、PDGF、VEGF与肺功能检查及血氧分压的相关性
指　标 FEV1% FVC% DLCO% PaO2(mmHg)
γ P γ P γ P γ P
BALF                
TGF-β1 -0.674 0.000 -0.523 0.000 -0.411 0.000 -2.589 0.000
PDGF -0.576 0.000 -0.489 0.000 -0.401 0.000 -1.109 0.000
VEGF -0.441 0.000 -0.378 0.000 -0.281 0.000 -0.351 0.000
血清                
TGF-β1 -0.805 0.000 -0.752 0.000 -0.602 0.000 -0.619 0.000
PDGF -0.685 0.000 -0.616 0.000 -0.495 0.000 -0.551 0.000
VEGF -0.521 0.000 -0.508 0.000 -0.389 0.000 -0.267 0.000
1
崔社怀. 特发性肺间质纤维化的回顾和展望[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3(1): 4-5.
2
Wu Q, Zhou Y, Feng FC, et al. Effectiveness and safety of Chinese medicine for Idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Chin J integr Med, 2019, 25(10): 778-784.
3
Marshall DC, Salciccioli JD, Shea BS, et al. Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an Observational study of the WHO mortality database from 2001-2013[J]. EurRespir J, 2018, 51(1): 1701603.
4
Gannon W, Lederer DJ, Biscotti M, et al. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease[J]. Chest, 2018, 3692(18): 30078-30073.
5
Kreuter M, Costabel U, Richeldi L, et al. Statin therapy and outcomes in trials of Nintedanib in Idiopathic pulmonary fibrosis[J]. Respiration, 2018, 95(5): 317-326.
6
Gabasa M, Duch P, Jorba I, et al. Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis[J]. Mol Biol Cell, 2017, 28(26): 3741-3755.
7
Li LC, Xu L, Hu Y, et al. Astragaloside Ⅳ improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition[J]. Front Pharmacol, 2017, 8(8): 513.
8
Nyp MF, Mabry SM, Navarro A, et al. Lung epithelial-specific TRIP-1 overexpression maintains epithelial integrity during hyperoxia exposure[J]. Physiol Rep, 2018, 6(5): doi: 10.14814/phy2.13585.
9
Zheng S, Wang Q, D′Souza V, et al. Resolvin D stimulates epithelial wound repair andinhibitsTGF-β-induced EMT whilst reducing fibroproliferation and collagen production[J]. Lab Invest, 2018, 98(1): 130-140.
10
Kishi M, Aono Y, Sato S, et al. Blockade of platelet-derived growth factor receptor-β，not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice[J]. PLoS One, 2018, 13(12): e0209786.
11
Barratt SL, Blythe T, Ourradi K, et al. Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in idiopathic pulmonary Fibrosis (IPF)[J]. Respir Res, 2018, 19(1): 9.
12
Povedano JM, Martinez P, Serrano R, et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres[J]. Elife, 2018, 30(7): e31299.
13
Torrisi SE, Palmucci S, Stefano A, et al. Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes[J]. Multidiscip Respir Med, 2018, 1(13): 43.
14
Yu SH, Liu LJ, Lv B, et al. Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-γ and TGF-β[J]. Cell Biochem Funct, 2015, 33(6): 356-366.
15
Ronan N, Bennett DM, Khan KA, et al. Tissue and Bronchoalveolar lavage biomarkers in idiopathic pulmonary fibrosis patients on pirfenidone[J]. Lung, 2018, 196(5): 543-552.
16
Alsumrain M, De Giacomi F, Nasim F, et al. Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: Characterization of presenting lung fibrosis and implications for survival[J]. Respir Med, 2019, 146: 106-112.
17
Ramos-Rossy J, Cantres-Fonseca O, Arzon-Nieves G, et al. Misleading diagnosis of idiopathic pulmonary fibrosis: A clinical concern[J]. Fed Pract, 2018, 35(2): 40-42.
18
Xie T, Liang J, Geng Y, et al. MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis[J]. Am J Respir Cell Mol Biol, 2017, 57(6): 721-732.
19
Kropski JA, Blackwell TS. Progress in understanding and treating Idiopathic Pulmonary Fibrosis[J]. Annu Rev Med, 2019, 27(70): 211-224.
20
Kolilekas L, Papiris S, Bouros D. Existing and emerging treatments for idiopathic pulmonary fibrosis[J]. Expert Rev Respir Med, 2019, 13(3): 229-239.
[1] 郑鲁丹, 陈敏, 张永渠, 张国君. 血小板衍生生长因子/血小板衍生生长因子受体信号通路在乳腺癌发生、发展中的作用[J]. 中华乳腺病杂志(电子版), 2022, 16(02): 116-120.
[2] 王博, 白子锐, 李坚. 近红外二区新型血管内皮生长因子受体靶向探针在结直肠癌小鼠模型中的应用[J]. 中华普通外科学文献(电子版), 2023, 17(03): 173-177.
[3] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[4] 王玉芹, 刘冠群, 曲福君. IDH1和VEGF对非小细胞肺癌的诊断意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 847-849.
[5] 何继强, 任安伟, 王飞. 周围型肺癌CT特征与PCNA、VEGF及Bcl-2表达水平的相关性[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 527-529.
[6] 林红卫, 李王平, 金发光. PM2.5激活HIF-1α-NF-κB/VEGF通路对肺损伤的影响[J]. 中华肺部疾病杂志(电子版), 2022, 15(03): 316-322.
[7] 杜文峰, 周玲, 李琪. 血清KL-6对特发性肺纤维化患者诊断及预后的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(02): 218-220.
[8] 刘雪娇, 盛伟利, 丁艳艳, 尹凤先. 特发性肺纤维化急性加重患者预后危险因素及意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(02): 212-214.
[9] 翁晓芹, 秦嘉阳, 张扬, 崔进, 沈红. HIF-1α/VEGF-VEGFR2/Nrp-1表达对NSCLC患者Treg增殖的影响[J]. 中华肺部疾病杂志(电子版), 2021, 14(06): 717-722.
[10] 崔宏宇, 杨一佺, 郭黎霞, 吕爱国, 张志宏, 张新, 杨艳萍, 申然, 连丽英, 曹志刚, 王立芳, 胡建华, 范肃洁. 改良Ahmed青光眼引流阀植入术治疗闭角期新生血管性青光眼疗效的临床研究[J]. 中华眼科医学杂志(电子版), 2023, 13(02): 76-81.
[11] 吴培培, 陈秀丽, 冯程程, 徐海峰. 玻璃体腔注射雷珠单抗联合地塞米松治疗视网膜中央静脉阻塞继发黄斑水肿的临床研究[J]. 中华眼科医学杂志(电子版), 2022, 12(01): 24-30.
[12] 吴晓翔, 杨波, 李景漩, 张凤玲, 郭桂辉, 郑少培. 脐动脉超声检查联合NLR、sFlt-1/PLGF对妊娠高血压综合征患者不良妊娠结局的预测价值[J]. 中华临床医师杂志(电子版), 2023, 17(03): 266-271.
[13] 李辉, 李海霞, 王秀香. 血必净注射液辅助治疗原发性肝癌介入术后综合征的临床研究[J]. 中华介入放射学电子杂志, 2022, 10(01): 27-31.
[14] 颜凡辉, 赵明俐, 李颖, 郭方明, 詹景冬, 赵英杰, 王阳, 张艳芬, 赵笑梅. 急性冠脉综合征患者冠脉血管病变程度与血清TNF-α、VEGF水平相关性研究[J]. 中华诊断学电子杂志, 2023, 11(03): 158-164.
[15] 吕昆明, 王沙沙, 万军, 令狐恩强. 胃食管反流病与特发性肺纤维化关系的研究进展[J]. 中华胃肠内镜电子杂志, 2023, 10(02): 121-124.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号